Chun-Ming Tsai

Chun-Ming Tsai

Auto-generated profile, based on publicly available information

Chun-Ming Tsai

Section of Thoracic Oncology, Chest Department, Taipei Veterans General Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2008 in Respirology
Verified
Journal Article
Closed access
PDF file
HSHsuan‐Tsung Su
Hsuan‐Tsung Su
CTChun‐Ming Tsai
Chun‐Ming Tsai
RPReury‐Perng Perng
Reury‐Perng Perng

1 March 2011 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
CTChun-Ming Tsai
Chun-Ming Tsai
JCJen-Ting Chen
Jen-Ting Chen
DSDavid J. Stewart
David J. Stewart
CCChao-Hua Chiu
Chao-Hua Chiu
CLChun-Liang Lai
Chun-Liang Lai
KCKuo-Ting Chang
Kuo-Ting Chang

30 November 2006 in Lung Cancer
Verified
Journal Article
Closed access
PDF file
WLWei-Chun Lin
Wei-Chun Lin
CCChao-Hua Chiu
Chao-Hua Chiu
JLJia-Ling Liou
Jia-Ling Liou
YCYuh-Min Chen
Yuh-Min Chen
RPReury-Perng Perng
Reury-Perng Perng
CTChun-Ming Tsai
Chun-Ming Tsai

22 November 2005 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
CLChun-Liang Lai
Chun-Liang Lai
CTChun-Ming Tsai
Chun-Ming Tsai
CCChao-Hua Chiu
Chao-Hua Chiu
GWGwo-Shu Wang
Gwo-Shu Wang
WSWei-Juin Su
Wei-Juin Su
RPReury-Perng Perng
Reury-Perng Perng
Background: For orientals, titrating doses of docetaxel (60–66 mg/m2) have shown equal effectiveness and fewer side effects as a second-line chemotherapy for patients with advanced non-small cell lung cancer (NSCLC). Under such doses, there were no comparative data between classic tri-weekly and Days 1 and 8 weekly schedules. Methods: This Phase II randomized prospective study was designed to compare the toxicity profile, efficacy and quality-of-life (QOL) between these two schedules of docetaxel in the treatment of previously treated patients with advanced NSCLC. Fifty patients were randomized to docetaxel arm A (66 mg/m2 Day 1) and B (33 mg/m2 Days 1 and 8) given every 3 weeks. Results: The overall response rates (ORRs) were 12 and 24% in arm A and B, respectively (P = 0.46), and disease control rates were 52 and 48%. The median time-to-progression (TTP) was 11.3 and 12.7 weeks and median survivals were 33.4 and 27.6 weeks, respectively. Both arms have same 1 year (36%) and 2 year survivals (12%). Arm A had significantly higher neutropenia but less compromised QOL. In this study, the response of second-line chemotherapy was significantly better in the group that was response to front-line chemotherapy (P = 0.032). Conclusions: While Days 1 and 8 weekly docetaxel schedules show higher ORR and less hematological toxicity, there is no advantage to tri-week schedule in terms of TTP and survival, but more compromised QOL.

1 June 2011 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
CTChun-Ming Tsai
Chun-Ming Tsai
JAJoseph Siu-Kie Au
Joseph Siu-Kie Au
GCGee-Chen Chang
Gee-Chen Chang
ACAshley Chi-Kin Cheng
Ashley Chi-Kin Cheng
CZCaicun Zhou
Caicun Zhou
YWYI-LONG WU
YI-LONG WU

1 August 2012 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
CTChun-Ming Tsai
Chun-Ming Tsai
CCChao-Hua Chiu
Chao-Hua Chiu
KCKao-Ting Chang
Kao-Ting Chang
JCJen-Ting Chen
Jen-Ting Chen
CLChun-Liang Lai
Chun-Liang Lai
SHShih-Yin Hsiao
Shih-Yin Hsiao